|
ATP8B2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.43294314986542E-13 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.22044604925031E-16 |
| Normal-vs-Stage2 |
4.88165063927681E-13 |
| Normal-vs-Stage3 |
5.32907051820075E-15 |
| Normal-vs-Stage4 |
7.17204073907851E-14 |
| Stage1-vs-Stage2 |
5.259900E-02 |
| Stage1-vs-Stage3 |
2.372800E-01 |
| Stage1-vs-Stage4 |
1.961840E-02 |
| Stage2-vs-Stage3 |
3.202000E-01 |
| Stage2-vs-Stage4 |
9.565800E-01 |
| Stage3-vs-Stage4 |
2.793600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.43516359591467E-13 |
| Normal-vs-AfricanAmerican |
2.209800E-04 |
| Normal-vs-Asian |
8.64050000437544E-08 |
| Caucasian-vs-AfricanAmerican |
2.518200E-01 |
| Caucasian-vs-Asian |
1.410760E-01 |
| AfricanAmerican-vs-Asian |
7.389000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
3.94295707195624E-12 |
| Male-vs-Female |
1.427960E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.99830160699344E-11 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.63813407283442E-12 |
| Normal-vs-Age(81-100Yrs) |
4.756500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.455000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.821300E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.401000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.095040E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.020600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.722000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.840500E-04 |
| Classical-VS-Follicular |
2.342800E-03 |
| Classical-VS-Other |
3.066400E-01 |
| Classical-VS-Normal |
6.91899870730595E-11 |
| Tall-VS-Follicular |
8.147400E-01 |
| Tall-VS-Other |
7.901800E-01 |
| Tall-VS-Normal |
1.68354219454159E-12 |
| Follicular-VS-Other |
8.656200E-01 |
| Follicular-VS-Normal |
1.63324909152607E-12 |
| Other-VS-Normal |
5.236300E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
9.03721542044877E-14 |
| Normal-vs-N1 |
3.18356452311264E-12 |
| N0-vs-N1 |
9.525800E-01 |
|
|
